Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Apr;23(4):1104-10.
doi: 10.1245/s10434-015-4934-0. Epub 2015 Oct 28.

Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer

Yuka Asano  1 , Shinichiro Kashiwagi  2 , Naoyoshi Onoda  1 , Satoru Noda  1 , Hidemi Kawajiri  1 , Tsutomu Takashima  1 , Masahiko Ohsawa  3 , Seiichi Kitagawa  4 , Kosei Hirakawa  1
Affiliations
Clinical Trial

Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer

Yuka Asano et al. Ann Surg Oncol. 2016 Apr.

Abstract

Background: The neutrophil/lymphocyte ratio (NLR) has been reportedly associated with prognosis in cancer patients by influencing both cancer progression and chemosensitivity. However, the correlation between NLR and the outcome of neoadjuvant chemotherapy (NAC) in breast cancer patients remains unclear.

Methods: NLR was evaluated in 177 patients with breast cancer treated with NAC with 5-fluorouracil, epirubicin, and cyclophosphamide, followed by weekly paclitaxel and subsequent curative surgery. The correlation between NLR and prognosis, including the efficacy of NAC, was evaluated retrospectively.

Results: NLR ranged from 0.5 to 10.6. Fifty-eight patients with low NLR (<3.0) had a higher pathological complete response (pCR) rate (p < 0.001) and were more frequently diagnosed with ER-negative/progesterone receptor (PR)-negative/HER2-negative (triple-negative) breast cancer (TNBC; p < 0.001) compared with patients with high NLR (≥3.0). Among TNBC patients who achieved pCR, disease-free survival (p = 0.006) and overall survival (p < 0.001) were significantly longer in patients with low NLR than in those with high NLR. Low NLR was associated with a significantly favorable prognosis in TNBC patients who achieved pCR, according to univariate analysis (p = 0.044, hazard ratio = 0.06).

Conclusions: Low NLR may indicate high efficacy and favorable outcome after NAC in patients with TNBC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
There was no significant difference in disease-free survival (DFS) in relation to NLR among all 177 breast cancer patients (a), or among 61 TNBC patients (b). However, among TNBC patients who achieved pCR, DFS (p = 0.006) was significantly longer in patients with low NLR after NAC, compared with patients with high NLR (c)
Fig. 2
Fig. 2
There was no significant difference in overall survival (OS) in relation to NLR among all 177 breast cancer patients (a), or among 61 TNBC patients (b). However, among TNBC patients who achieved pCR, OS (p < 0.001) was significantly longer in patients with low NLR after NAC compared with patients with high NLR (c)
See this image and copyright information in PMC

References

    1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102. doi: 10.1093/oxfordjournals.jncimonographs.a003469. - DOI - PubMed
    1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19(22):4224–4237. - PubMed
    1. Mayer EL, Carey LA, Burstein HJ. Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007;9(5):110. doi: 10.1186/bcr1755. - DOI - PMC - PubMed
    1. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11(6):574–589. doi: 10.1634/theoncologist.11-6-574. - DOI - PubMed
    1. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165–4174. doi: 10.1200/JCO.2003.12.005. - DOI - PubMed

Publication types

MeSH terms